A detailed history of Scotia Capital Inc. transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Scotia Capital Inc. holds 14,740 shares of ABUS stock, worth $53,506. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14,740
Previous 18,740 21.34%
Holding current value
$53,506
Previous $57,000 1.75%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$3.12 - $4.56 $12,480 - $18,240
-4,000 Reduced 21.34%
14,740 $56,000
Q2 2024

Aug 14, 2024

SELL
$2.52 - $3.63 $25,956 - $37,389
-10,300 Reduced 35.47%
18,740 $57,000
Q2 2023

Aug 03, 2023

SELL
$2.24 - $3.06 $336 - $459
-150 Reduced 0.51%
29,040 $66,000
Q1 2023

May 11, 2023

BUY
$2.23 - $3.1 $65,093 - $90,489
29,190 New
29,190 $88,000
Q3 2021

Nov 12, 2021

SELL
$2.65 - $4.62 $30,978 - $54,007
-11,690 Closed
0 $0
Q1 2021

May 06, 2021

SELL
$3.14 - $4.84 $442 - $682
-141 Reduced 1.19%
11,690 $39,000
Q4 2020

Feb 11, 2021

BUY
$2.76 - $4.97 $27 - $49
10 Added 0.08%
11,831 $42,000
Q3 2020

Nov 12, 2020

BUY
$1.75 - $6.2 $229 - $812
131 Added 1.12%
11,821 $37,000
Q1 2020

May 15, 2020

BUY
$1.01 - $3.42 $40 - $136
40 Added 0.34%
11,690 $12,000
Q4 2019

Feb 13, 2020

SELL
$0.87 - $2.89 $6,960 - $23,120
-8,000 Reduced 40.71%
11,650 $32,000
Q3 2019

Nov 14, 2019

SELL
$1.34 - $2.4 $4,020 - $7,200
-3,000 Reduced 13.25%
19,650 $30,000
Q2 2019

Aug 13, 2019

SELL
$1.46 - $4.44 $292 - $888
-200 Reduced 0.88%
22,650 $47,000
Q3 2018

Nov 14, 2018

SELL
$7.85 - $12.35 $48,670 - $76,570
-6,200 Reduced 21.34%
22,850 $216,000
Q4 2017

Feb 13, 2018

SELL
$4.45 - $7.7 $11,570 - $20,020
-2,600 Reduced 8.21%
29,050 $147,000
Q3 2017

Nov 14, 2017

BUY
$3.4 - $7.0 $34,510 - $71,050
10,150 Added 47.21%
31,650 $196,000
Q2 2017

Aug 15, 2017

BUY
N/A
21,500
21,500 $77,000

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $544M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Scotia Capital Inc. Portfolio

Follow Scotia Capital Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Scotia Capital Inc., based on Form 13F filings with the SEC.

News

Stay updated on Scotia Capital Inc. with notifications on news.